Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wallace, Eric L
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease	Active, not recruiting	3	122	Europe, Canada, Japan, US, RoW	Venglustat (GZ402671), Placebo	Sanofi, Sanofi-Aventis Recherche & Développement	Fabry Disease	12/25	12/26
NCT04552691: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients	Approved for marketing	N/A		US	Pegunigalsidase Alfa	Chiesi Farmaceutici S.p.A., Chiesi USA, Inc.	Fabry Disease
FROST-HF, NCT05136820: Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study	Active, not recruiting	N/A	698	US	Atrial Flow Regulator, AFR, Sham Comparator	Occlutech International AB	Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)	02/26	02/29
Rattan, Jesse E
AW2H, NCT06353256: A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes	Recruiting	N/A	60	US	usual postpartum care, usual postpartum care + community health worker intervention	University of Alabama at Birmingham, American Heart Association, National Institutes of Health (NIH)	Preeclampsia Postpartum, Adverse Pregnancy Outcomes	07/25	07/25